Membranoproliferative glomerulonephritis epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Line 72: Line 72:
== Epidemiology of specific glomerular disease ==
== Epidemiology of specific glomerular disease ==
By dividing glomerular diseases into two subtypes, which are Nephrotic or Nephritic, subdividing into several specific disease will be much more easier.{{Membranoproliferative glomerulonephritis}}
By dividing glomerular diseases into two subtypes, which are Nephrotic or Nephritic, subdividing into several specific disease will be much more easier.{{Membranoproliferative glomerulonephritis}}
{| style="border: 3px; margin: 1px; font-size: 90%; width: 700px; align=" center "
! colspan="6" style="background: #5579ff; width 700px; " | {{fontcolor|#FFF|Temporal trends in the renal biopsy frequencies of glomerular disease subtypes among patients with specified glomerular disease diagnoses*}}
|-
! colspan="2" style="background: #4479ba; " | {{fontcolor|#FFF| demographic variables}}
! style="background: #4479ba; " | {{fontcolor|#FFF| 1986-1995, %}}
! style="background: #4479ba; " | {{fontcolor|#FFF| 1996-2005, %}}
! style="background: #4479ba; " | {{fontcolor|#FFF| 2006-2015, %}}
! style="background: #4479ba; " | {{fontcolor|#FFF| Total, %}}
|-
! rowspan="11" style="padding: 4px 4px; background: #00AF89; " | {{fontcolor|#FFF| Nephrotic subtypes}}
! style="padding: 3px 3px; background: #B0E0E6; " | FSGS
! style="padding: 3px 3px; background: #E0FFFF; " | 22.6
! style="padding: 3px 3px; background: #E0FFFF; " | 27.2
! style="padding: 3px 3px; background: #E0FFFF; " | 24.7
! style="padding: 3px 3px; background: #E0FFFF; " | 25.3
|-
! style="padding: 3px 3px; background: #B0E0E6; " | Diabetic glomerulosclerosis
! style="padding: 3px 3px; background: #E0FFFF; " | 5.5
! style="padding: 3px 3px; background: #E0FFFF; " | 11.4
! style="padding: 3px 3px; background: #E0FFFF; " | 19.1
! style="padding: 3px 3px; background: #E0FFFF; " | 14.2
|-
! style="padding: 3px 3px; background: #B0E0E6; " | Membranous nephropathy
! style="padding: 3px 3px; background: #E0FFFF; " | 17.8
! style="padding: 3px 3px; background: #E0FFFF; " | 13.8
! style="padding: 3px 3px; background: #E0FFFF; " | 10.6
! style="padding: 3px 3px; background: #E0FFFF; " | 12.9
|-
! style="padding: 3px 3px; background: #B0E0E6; " | Minimal change disease
! style="padding: 3px 3px; background: #E0FFFF; " | 8.8
! style="padding: 3px 3px; background: #E0FFFF; " | 5.5
! style="padding: 3px 3px; background: #E0FFFF; " | 4.1
! style="padding: 3px 3px; background: #E0FFFF; " | 5.3
|-
! style="padding: 3px 3px; background: #FFA07A; " | MPGN
! style="padding: 3px 3px; background: #E0FFFF; " | 4.5
! style="padding: 3px 3px; background: #E0FFFF; " | 2.9
! style="padding: 3px 3px; background: #E0FFFF; " | 2.5
! style="padding: 3px 3px; background: #E0FFFF; " | 3.0
|-
! style="padding: 3px 3px; background: #B0E0E6; " | Amyloidosis
! style="padding: 3px 3px; background: #E0FFFF; " | 2.2
! style="padding: 3px 3px; background: #E0FFFF; " | 2.0
! style="padding: 3px 3px; background: #E0FFFF; " | 2.5
! style="padding: 3px 3px; background: #E0FFFF; " | 2.3
|-
! style="padding: 3px 3px; background: #B0E0E6; " | MIDD
! style="padding: 3px 3px; background: #E0FFFF; " | 0.6
! style="padding: 3px 3px; background: #E0FFFF; " | 0.6
! style="padding: 3px 3px; background: #E0FFFF; " | 1.6
! style="padding: 3px 3px; background: #E0FFFF; " | 1.1
|-
! style="padding: 3px 3px; background: #B0E0E6; " | Dense deposit disease
! style="padding: 3px 3px; background: #E0FFFF; " | 2.2
! style="padding: 3px 3px; background: #E0FFFF; " | 2.0
! style="padding: 3px 3px; background: #E0FFFF; " | 2.5
! style="padding: 3px 3px; background: #E0FFFF; " | 2.3
|-
! style="padding: 3px 3px; background: #B0E0E6; " | Fabry disease
! style="padding: 3px 3px; background: #E0FFFF; " | 0.1
! style="padding: 3px 3px; background: #E0FFFF; " | 0.1
! style="padding: 3px 3px; background: #E0FFFF; " | 0.0
! style="padding: 3px 3px; background: #E0FFFF; " | 0.1
|-
! style="padding: 3px 3px; background: #B0E0E6; " | Collagenofibrotic glomerulopathy
! style="padding: 3px 3px; background: #E0FFFF; " | 0.1
! style="padding: 3px 3px; background: #E0FFFF; " | 0.0
! style="padding: 3px 3px; background: #E0FFFF; " | 0.0
! style="padding: 3px 3px; background: #E0FFFF; " | 0.0
|-
! style="padding: 3px 3px; background: #B0E0E6; " | Total
! style="padding: 3px 3px; background: #E0FFFF; " | 52.4
! style="padding: 3px 3px; background: #E0FFFF; " | 63.7
! style="padding: 3px 3px; background: #E0FFFF; " | 65.3
! style="padding: 3px 3px; background: #E0FFFF; " | 64.3
|-
! rowspan="9" style="padding: 4px 4px; background: #00AF89; " | {{fontcolor|#FFF| Nephritic subtypes}}
! style="padding: 3px 3px; background: #B0E0E6; " | Lupus nephritis
! style="padding: 3px 3px; background: #E0FFFF; " | 12.8
! style="padding: 3px 3px; background: #E0FFFF; " | 13.9
! style="padding: 3px 3px; background: #E0FFFF; " | 11.2
! style="padding: 3px 3px; background: #E0FFFF; " | 12.5
|-
! style="padding: 3px 3px; background: #B0E0E6; " | IgAN
! style="padding: 3px 3px; background: #E0FFFF; " | 10.2
! style="padding: 3px 3px; background: #E0FFFF; " | 11.4
! style="padding: 3px 3px; background: #E0FFFF; " | 9.4
! style="padding: 3px 3px; background: #E0FFFF; " | 10.3
|-
! style="padding: 3px 3px; background: #B0E0E6; " | ANCA/pauci-immune GN
! style="padding: 3px 3px; background: #E0FFFF; " | 9.3
! style="padding: 3px 3px; background: #E0FFFF; " | 6.8
! style="padding: 3px 3px; background: #E0FFFF; " | 8.3
! style="padding: 3px 3px; background: #E0FFFF; " | 7.9
|-
! style="padding: 3px 3px; background: #B0E0E6; " | TBM lesion
! style="padding: 3px 3px; background: #E0FFFF; " | 1.9
! style="padding: 3px 3px; background: #E0FFFF; " | 1.3
! style="padding: 3px 3px; background: #E0FFFF; " | 3.0
! style="padding: 3px 3px; background: #E0FFFF; " | 2.2
|-
! style="padding: 3px 3px; background: #B0E0E6; " | Fibrillary GN
! style="padding: 3px 3px; background: #E0FFFF; " | 1.5
! style="padding: 3px 3px; background: #E0FFFF; " | 1.2
! style="padding: 3px 3px; background: #E0FFFF; " | 1.4
! style="padding: 3px 3px; background: #E0FFFF; " | 1.4
|-
! style="padding: 3px 3px; background: #B0E0E6; " | Anti-GBM nephritis
! style="padding: 3px 3px; background: #E0FFFF; " | 1.1
! style="padding: 3px 3px; background: #E0FFFF; " | 1.0
! style="padding: 3px 3px; background: #E0FFFF; " | 0.8
! style="padding: 3px 3px; background: #E0FFFF; " | 0.9
|-
! style="padding: 3px 3px; background: #B0E0E6; " | Alport syndrome
! style="padding: 3px 3px; background: #E0FFFF; " | 0.6
! style="padding: 3px 3px; background: #E0FFFF; " | 0.4
! style="padding: 3px 3px; background: #E0FFFF; " | 0.5
! style="padding: 3px 3px; background: #E0FFFF; " | 0.5
|-
! style="padding: 3px 3px; background: #B0E0E6; " | Immunotactoid GN
! style="padding: 3px 3px; background: #E0FFFF; " | 0.2
! style="padding: 3px 3px; background: #E0FFFF; " | 0.1
! style="padding: 3px 3px; background: #E0FFFF; " | 0.1
! style="padding: 3px 3px; background: #E0FFFF; " | 0.1
|-
! style="padding: 3px 3px; background: #B0E0E6; " | Total
! style="padding: 3px 3px; background: #E0FFFF; " | 37.6
! style="padding: 3px 3px; background: #E0FFFF; " | 36.3
! style="padding: 3px 3px; background: #E0FFFF; " | 34.7
! style="padding: 3px 3px; background: #E0FFFF; " | 35.7
|-
! colspan="6" style="background: #5579ff; width 700px; " | {{fontcolor|#FFF|*These are datas for USA population}}
|}


==References==
==References==

Revision as of 07:23, 22 July 2018


Overview

Since Membranoproliferative Glomerulonephritis (MPGN) is a small portion of all glomerular disease, there is not enough evidence to completely demonstrate the epidemiology of this specific category.

Albeit, there are strong valid studies demonstrate the incidence and prevalence of all glomerular diseases.

Correlation of age and sex with glomerular disease

Due to the pathophysiology of glomerular disease, incidence of most of the glomerular disease is in middle-age group. Albeit there are some categorizes that could occurred during childhood.

Age-adjusted trends in patient demographics among patients with specified glomerular disease diagnoses*
demographic variables 1986-1995, % 1996-2005, % 2006-2015, % Total, %
Gender Male 51.9 50.1 51.1 50.8
Female 48 49.1 48.8 48.9
missing sex 0.1 0.8 0.1 0.3
Race White 64.1 56.5 54.7 56.8
Black 34.5 39.9 38.2 38.3
Latino 0.6 1.8 4.2 2.8
Asian 0.0 1.0 2.0 1.4
Other 0.8 0.6 0.9 0.8
*These are datas for USA population

Epidemiology of specific glomerular disease

By dividing glomerular diseases into two subtypes, which are Nephrotic or Nephritic, subdividing into several specific disease will be much more easier.

Membranoproliferative glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Membranoproliferative glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Membranoproliferative glomerulonephritis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Membranoproliferative glomerulonephritis epidemiology and demographics

CDC on Membranoproliferative glomerulonephritis epidemiology and demographics

Membranoproliferative glomerulonephritis epidemiology and demographics in the news

Blogs on Membranoproliferative glomerulonephritis epidemiology and demographics

Directions to Hospitals Treating Membranoproliferative glomerulonephritis

Risk calculators and risk factors for Membranoproliferative glomerulonephritis epidemiology and demographics

Temporal trends in the renal biopsy frequencies of glomerular disease subtypes among patients with specified glomerular disease diagnoses*
demographic variables 1986-1995, % 1996-2005, % 2006-2015, % Total, %
Nephrotic subtypes FSGS 22.6 27.2 24.7 25.3
Diabetic glomerulosclerosis 5.5 11.4 19.1 14.2
Membranous nephropathy 17.8 13.8 10.6 12.9
Minimal change disease 8.8 5.5 4.1 5.3
MPGN 4.5 2.9 2.5 3.0
Amyloidosis 2.2 2.0 2.5 2.3
MIDD 0.6 0.6 1.6 1.1
Dense deposit disease 2.2 2.0 2.5 2.3
Fabry disease 0.1 0.1 0.0 0.1
Collagenofibrotic glomerulopathy 0.1 0.0 0.0 0.0
Total 52.4 63.7 65.3 64.3
Nephritic subtypes Lupus nephritis 12.8 13.9 11.2 12.5
IgAN 10.2 11.4 9.4 10.3
ANCA/pauci-immune GN 9.3 6.8 8.3 7.9
TBM lesion 1.9 1.3 3.0 2.2
Fibrillary GN 1.5 1.2 1.4 1.4
Anti-GBM nephritis 1.1 1.0 0.8 0.9
Alport syndrome 0.6 0.4 0.5 0.5
Immunotactoid GN 0.2 0.1 0.1 0.1
Total 37.6 36.3 34.7 35.7
*These are datas for USA population

References

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Membranoproliferative_glomerulonephritis_epidemiology_and_demographics&oldid=1484372"